A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Double-Strand Break Repair Pathway Deficient Neoplasms

Next Previous
Trial Profile

A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Double-Strand Break Repair Pathway Deficient Neoplasms

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Niraparib (Primary)
  • Indications Cholangiocarcinoma; Mesothelioma; Renal cell carcinoma; Uveal melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 1 Nov 2022 to 1 Dec 2022.
    • 09 Apr 2018 Planned primary completion date changed from 1 Nov 2021 to 1 Dec 2021.
    • 09 Apr 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top